The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Pfizer; Takeda
 
Giovanni Martinelli
Consulting or Advisory Role - ARIAD; Celgene; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis
 
Marco Vignetti
Consulting or Advisory Role - Jazz Pharmaceuticals; Millennium
Other Relationship - Pfizer
 
Josep-Maria Ribera
No Relationships to Disclose
 
David Gomez-Almaguer
Consulting or Advisory Role - Celgene; Janssen; Takeda
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb (Mexico); Janssen; Novartis
 
Yosuke Minami
Honoraria - Amgen; Novartis; Takeda
Research Funding - Ono Pharmaceutical
 
Jing Xu
Employment - Takeda
 
Shouryadeep Srivastava
Employment - Takeda
 
Frank Neumann
Employment - Takeda
 
Hagop M. Kantarjian
Honoraria - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; Immunogen; Orsenix; Pfizer; Takeda
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Daiichi Sankyo (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst)